CHEBI:27882 - (S)-colchicine

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name (S)-colchicine
ChEBI ID CHEBI:27882
ChEBI ASCII Name (S)-colchicine
Definition A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.
Stars This entity has been manually annotated by the ChEBI Team.
Secondary ChEBI IDs CHEBI:3811
Supplier Information
Download Molfile XML SDF
more structures >>
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C22H25NO6
Net Charge 0
Average Mass 399.443
Monoisotopic Mass 399.16819
InChI InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
InChIKey IAKHMKGGTNLKSZ-INIZCTEOSA-N
SMILES COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1[C@H](CC2)NC(C)=O
Roles Classification
Biological Role(s): mutagen
An agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
plant metabolite
Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
(via colchicine )
microtubule-destabilising agent
Any substance that interacts with tubulin to inhibit polymerisation of microtubules.
(via colchicine )
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
(via alkaloid )
Application(s): anti-inflammatory agent
Any compound that has anti-inflammatory effects.
gout suppressant
A drug that increases uric acid excretion by the kidney (uricosuric drug), decreases uric acid production (antihyperuricemic), or alleviates the pain and inflammation of acute attacks of gout.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing (S)-colchicine (CHEBI:27882) has role anti-inflammatory agent (CHEBI:67079)
(S)-colchicine (CHEBI:27882) has role gout suppressant (CHEBI:35845)
(S)-colchicine (CHEBI:27882) has role mutagen (CHEBI:25435)
(S)-colchicine (CHEBI:27882) is a alkaloid (CHEBI:22315)
(S)-colchicine (CHEBI:27882) is a colchicine (CHEBI:23359)
(S)-colchicine (CHEBI:27882) is enantiomer of (R)-colchicine (CHEBI:51074)
Incoming (R)-colchicine (CHEBI:51074) is enantiomer of (S)-colchicine (CHEBI:27882)
IUPAC Name
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
Synonyms Sources
(−)-colchicine ChEBI
(S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide NIST Chemistry WebBook
H-colchicine NIST Chemistry WebBook
Colchicin ChemIDplus
colchicina DrugBank
Colchicine KEGG COMPOUND
colchicinum DrugBank
Brand Names Sources
Colchisol ChemIDplus
Colcin ChemIDplus
Colcrys ChemIDplus
Colsaloid ChemIDplus
Condylon ChemIDplus
Goutnil ChemIDplus
Kolkicin ChemIDplus
Mitigare ChemIDplus
Manual Xrefs Databases
5933 ChemSpider
726 DrugCentral
C00002327 KNApSAcK
C07592 KEGG COMPOUND
Colchicine Wikipedia
CPD-9785 MetaCyc
D00570 KEGG DRUG
DB01394 DrugBank
LOC PDBeChem
LSM-5199 LINCS
View more database links
Registry Numbers Types Sources
2228813 Beilstein Registry Number Beilstein
64-86-8 CAS Registry Number KEGG COMPOUND
64-86-8 CAS Registry Number ChemIDplus
64-86-8 CAS Registry Number NIST Chemistry WebBook
Citations Waiting for Citations Types Sources
16188942 PubMed citation Europe PMC
17619668 PubMed citation Europe PMC
18787557 PubMed citation Europe PMC
24530796 PubMed citation Europe PMC
28832953 PubMed citation Europe PMC
28912485 PubMed citation Europe PMC
28959419 PubMed citation Europe PMC
30565859 PubMed citation Europe PMC
32025680 PubMed citation Europe PMC
32426001 PubMed citation Europe PMC
32511763 PubMed citation Europe PMC
32837853 PubMed citation Europe PMC
32865380 PubMed citation Europe PMC
33100196 PubMed citation Europe PMC
33166069 PubMed citation Europe PMC
Last Modified
30 November 2020